Invivyd, Inc.
NASDAQ:IVVDBiotechnology
+$0.04 today
- Market cap
- $138.68M
- Beta
- 0.63
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$0.25
Volume 6.71M
Average 3.62M
IVVD Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Invivyd, Inc.NASDAQ: IVVD
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $2.7M fell 4.6% year over year, ahead of the -33.2% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 5.2% from the prior quarter. Over 3 fiscal years it compounded at -18.7% a year.
Context
- Stock-based compensation amounted to 21.8% of revenue in FY2025, down 56.2 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -4.6% holds above the trailing-twelve-month pace of -33.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 11.64M USD
- Year-over-year change
- -41.2%
- 4-year CAGR
- -10.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.64M | -41.2% |
| FY2024 | 2024-12-31 | 19.79M | +5.9% |
| FY2023 | 2023-12-31 | 18.69M | -13.7% |
| FY2022 | 2022-12-31 | 21.65M | +21.9% |
| FY2021 | 2021-12-31 | 17.76M | — |
Stock-Based Compensation vs competitors
How IVVD compares with its peers on the latest reported figures
- IVVD's LTM Mar 2026 stock-based compensation of $11.51M is the 5th largest of the 10 companies compared; the peer median is $8.67M.
- Its year-over-year change of -33.2% is the 7th highest of 9, against a peer median of -8.4%.
- Stock-based compensation amounts to 20.6% of revenue for IVVD, versus a peer median of 41.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.26M | -43.8% | -14.0% | 46.7% | |
| LTM Mar 2026 | $15.21M | — | — | — | |
| LTM Mar 2026 | $15.02M | -24.7% | -4.8% | 52.0% | |
| LTM Mar 2026 | $11.86M | +7.9% | +52.0% | 36.3% | |
| LTM Mar 2026 | $11.51M | -33.2% | -18.7% | 20.6% | |
| LTM Mar 2026 | $8.67M | -29.5% | -12.8% | 11.1% | |
| LTM Mar 2026 | $7.48M | -39.0% | -34.0% | 21.6% | |
| LTM Mar 2026 | $4.36M | +16.7% | -17.0% | — | |
| LTM Sep 2026 | $4.19M | +122.7% | +4.3% | — | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $2.4M | +50.7% | -39.5% | 123.1% |
| Peer median (excluding IVVD) | $8.67M | -8.4% | -13.4% | 41.5% | |
Competitors are the stored peer set for IVVD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (226.79M) | (241.32M) | (198.64M) | (169.93M) | (52.49M) |
| Depreciation & Amortization | 1K | 462K | 2.03M | 3.11M | 2.11M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 17.76M | 21.65M | 18.69M | 19.79M | 11.64M |
| Change in Working Capital | 22.79M | (16.13M) | 5.89M | (23.47M) | (19.69M) |
| Accounts Receivables | 0 | 0 | 0 | (10.91M) | (3.34M) |
| Inventory | 0 | 0 | 0 | (24.89M) | (373K) |
| Accounts Payables | (2.37M) | (4.3M) | 6.47M | 2.42M | 3.21M |
| Other Working Capital | 25.16M | (11.83M) | (583K) | 9.91M | (19.2M) |
| Other Non-Cash Items | 1.5M | 15.35M | (1.12M) | 19.79M | 298K |
| Operating Cash Flow | (184.74M) | (219.99M) | (173.16M) | (170.49M) | (58.14M) |
| Capital Expenditures | (84K) | (1.71M) | (615K) | (140K) | (155K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (188.63M) | (297.96M) | (91.2M) | 0 | 0 |
| Sales of Investments | 138M | 69M | 372.5M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (50.71M) | (230.67M) | 280.68M | (140K) | (155K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 330.91M | 510K | 1.2M | 39.29M | 215.63M |
| Common Stock Repurchased | 0 | (4K) | (1K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.39M) | 510K | 1.05M | 46K | 0 |
| Financing Cash Flow | 662.68M | 506K | 1.05M | 39.33M | 215.63M |
| Effect of Forex Changes | 0 | 0 | 0 | 8K | 0 |
| Net Change in Cash | 427.24M | (450.15M) | 108.57M | (131.29M) | 157.34M |
| Free Cash Flow | (184.82M) | (221.69M) | (173.78M) | (170.63M) | (58.29M) |
Invivyd, Inc.
NASDAQ:IVVD
Intrinsic Alpha fair value
Locked
Current Price
$0.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.